Updated recommendations from the Spanish Oncology Genitourinary Group for the treatment of patients with metastatic castration-resistant prostate cancer
| Autor: | Jesús García-Donas, Luis León-Mateos, Aranzazu Gonzalez del Alba, Begoña Mellado, Jose Angel Arranz, Josep Mª Piulats, Begoña Perez-Valderrama, Alfredo Sánchez-Hernández, Miguel Angel Climent, Javier Cassinello, Mª José Méndez-Vidal |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Male
Oncology medicine.medical_specialty Chemotherapy business.industry Genitourinary system medicine.medical_treatment Antineoplastic Agents Hematology Evidence-based medicine Disease Malignancy medicine.disease Castration-Resistant Prostate Carcinoma Prostatic Neoplasms Castration-Resistant Prostate cancer Internal medicine Humans Medicine business Progressive disease |
| Zdroj: | Critical Reviews in Oncology/Hematology. 96:308-318 |
| ISSN: | 1040-8428 |
| Popis: | Prostate cancer is the most prevalent male urogenital malignancy. Approximately 30% of patients with prostate cancer will develop advanced disease. Androgen deprivation therapy achieves disease control in about 90% of these patients, but the majority of them will eventually develop progressive disease, a status called castration-resistant prostate carcinoma (CRPC). However, in recent years, several new therapy strategies, such as immunotherapy, hormonal manipulations, chemotherapy agents and some bone-targeted therapies, have demonstrated an improvement in terms of overall survival in controlled trials. In 2012, the Spanish Oncology Genitourinary Group (SOGUG) published its recommendations for the treatment of patients with CRPC. Due to the recent appearance of important new data and the complexity of decision-making in this field, SOGUG herein provides updated recommendations for the treatment of patients with metastatic prostate cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect